These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 16983094)

  • 21. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma.
    Perera AD; Kleymenova EV; Walker CL
    Clin Cancer Res; 2000 Apr; 6(4):1518-23. PubMed ID: 10778984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
    Petrella BL; Brinckerhoff CE
    Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2'-hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL-mutant renal cell carcinoma.
    Nagaprashantha LD; Vatsyayan R; Singhal J; Lelsani P; Prokai L; Awasthi S; Singhal SS
    Carcinogenesis; 2011 Apr; 32(4):568-75. PubMed ID: 21304051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients.
    Mans DA; Vermaat JS; Weijts BG; van Rooijen E; van Reeuwijk J; Boldt K; Daenen LG; van der Groep P; Rowland BD; Jans JJ; Roepman R; Voest EE; van Diest PJ; Verhaar MC; de Bruin A; Giles RH
    J Pathol; 2013 Sep; 231(1):117-29. PubMed ID: 23744542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
    Lee SJ; Lattouf JB; Xanthopoulos J; Linehan WM; Bottaro DP; Vasselli JR
    Eur Urol; 2008 Oct; 54(4):845-53. PubMed ID: 18243508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
    Lieubeau-Teillet B; Rak J; Jothy S; Iliopoulos O; Kaelin W; Kerbel RS
    Cancer Res; 1998 Nov; 58(21):4957-62. PubMed ID: 9810005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer.
    Hirata H; Hinoda Y; Ueno K; Nakajima K; Ishii N; Dahiya R
    Carcinogenesis; 2012 Mar; 33(3):501-8. PubMed ID: 22180573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.
    Mukhopadhyay D; Knebelmann B; Cohen HT; Ananth S; Sukhatme VP
    Mol Cell Biol; 1997 Sep; 17(9):5629-39. PubMed ID: 9271438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta-catenin gets jaded and von Hippel-Lindau is to blame.
    Berndt JD; Moon RT; Major MB
    Trends Biochem Sci; 2009 Mar; 34(3):101-4. PubMed ID: 19217300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.
    Gunaratnam L; Morley M; Franovic A; de Paulsen N; Mekhail K; Parolin DA; Nakamura E; Lorimer IA; Lee S
    J Biol Chem; 2003 Nov; 278(45):44966-74. PubMed ID: 12944410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
    Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B
    Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
    Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
    J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
    Petrella BL; Lohi J; Brinckerhoff CE
    Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of Von Hippel-Lindau (
    Kim H; Shim BY; Lee SJ; Lee JY; Lee HJ; Kim IH
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
    Liu C; Liu L; Wang K; Li XF; Ge LY; Ma RZ; Fan YD; Li LC; Liu ZF; Qiu M; Hao YC; Shi ZF; Xia CY; Strååt K; Huang Y; Ma LL; Xu D
    Oncogene; 2020 May; 39(21):4286-4298. PubMed ID: 32291411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma.
    Ananth S; Knebelmann B; Grüning W; Dhanabal M; Walz G; Stillman IE; Sukhatme VP
    Cancer Res; 1999 May; 59(9):2210-6. PubMed ID: 10232610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
    Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
    Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NADPH oxidase NOX4 supports renal tumorigenesis by promoting the expression and nuclear accumulation of HIF2α.
    Gregg JL; Turner RM; Chang G; Joshi D; Zhan Y; Chen L; Maranchie JK
    Cancer Res; 2014 Jul; 74(13):3501-3511. PubMed ID: 24755467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma.
    Zeng L; Bai M; Mittal AK; El-Jouni W; Zhou J; Cohen DM; Zhou MI; Cohen HT
    Cancer Res; 2013 Sep; 73(17):5371-80. PubMed ID: 23824745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.